Tumors escape immunological rejection by a diversity of mechanisms. In this report, we demonstrate that the colon cancer cell SW620 expresses functional Fas ligand (FasL), the triggering agent of Fas receptor (FasR)-mediated apoptosis within the immune system. FasL mRNA and cell surface FasL were detected in SW620 cells using reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemical staining, respectively. We show that SW620 kills Jurkat T cells in a Fas-mediated manner. FasR-specific antisense oligonucleotide treatment, which transiently inhibited FasR expression, completely protected Jurkat cells from killing by SW620. FasL-specific antisense oligonucleotide treatment of SW620 inhibited its Jurkat-killing activity. FasL has recently been established as a mediator of immune privilege in mouse retina and testis. Our finding that colon cancer cells express functional FasL suggests it may play an analogous role in bestowing immune privilege on human tumors. HT29 and SW620 colon cancer cells were found to express FasR mRNA and cell surface FasR using RT-PCR and immunofluorescence flow cytometry, respectively. However, neither of these cells underwent apoptosis after treatment by the anti-FasR agonistic monoclonal antibody CH11. Our results therefore suggest a Fas counterattack model for immune escape in colon cancer, whereby the cancer cells resist Fas-mediated T cell cytotoxicity but express functional FasL, an apoptotic death signal to which activated T cells are inherently sensitive.
C
ancers escape immune clearance by a diversity of mechanisms. Although these include evasive strategies to avoid immune recognition, such as disruption of T cellextracellular matrix interactions and aberration of antigen processing and presentation, tumors also engage in active modulation and suppression of immune cell function. Local immune suppression due to tumor-derived agents is a feature of many cancer types. Chemically induced mouse colon tumors have been shown to cause profound local suppression ofmucosal inimune function (1) . The local immune suppression associated with esophageal squamous carcinoma is mediated by a tumor-derived factor that results in suppression and ultimately apoptotic cell death of activated lymphocytes (2) . Well-established tumor-derived immune modulatory molecules include downregulatory cytokines, immunosuppressive aminosugars (free hexosamines) (3), and gangliosides (4, 5) .
Fas ligand (FasL) 1 is a key molecule in normal immune development, homeostasis, modulation, and function (6) . Ligation onto its receptor, FasR (CD95), on sensitized cells induces programmed cell death, or apoptosis. This Fasmediated apoptotic death signal has a number of important immunological roles. Fas-mediated apoptosis is involved in such functions as thymocyte clonal deletion and tolerance acquisition (7) , T cell activation-induced cell death (8) , immune response termination (9) , and T cell-mediated cytotoxicity (10) . Dysfunction of Fas-mediated apoptosis has been associated with lymphoproliferative diseases and autoimmunity in humans (11, 12) and mice (13) .
Recently, two reports established a role for FasL in the maintenance of immune privilege in mouse testis (14) and in the anterior chamber of the eye (15) . FasL expressed in these tissues induces apoptosis in activated lymphocytes that infiltrate these sites.
FasL has been found to be constitutively expressed in some NK lymphomas and T cell-type large granular lymphocyte leukemias--malignancies of cells that normally express FasL upon activation (16) . Because of its central role in lymphocyte modulation through delivery of an apoptotic death signal, we investigated the expression and function of FasL in gastrointestinal cancer cells as a candidate for tumor-derived immune modulation and hence tumor imnmne escape.
FasR expression and response are variable in human lymphoid (17, 18) and nonlymphoid malignancies (19) , and resistance to Fas-mediated cytotoxicity may contribute to tumor immune escape. Resistance to cellular apoptotic mechanisms in general is thought to contribute to tumorigenicity (20) , and recent studies have shown that known tumor promoters, including nicotine, inhibit both FasRand TNF-mediated apoptosis (21) . Resistance to FasR has been observed in HIV- (22) and HTLV-1 (23) -infected T cells and may contribute to viral immune escape. Because of its role in receiving and transducing the FasL-mediated apoptotic signal from cytotoxic T cells, and because dysfunction in the FasR-signaling pathway results in resistance to Fas-mediated cytotoxicity, we also assessed Fastk expression and function on gastrointestinal cancer cells.
Materials and Methods
Cells. OC1 and OC2 are human esophageal squamous carcinoma cell lines developed in our laboratory (24) . HT29 and SW620 human colon epithelial adenocarcinoma cell lines and the Jurkat human T leukemia cell line were obtained from American Type Culture Collection (Rockville, MD). All cells were grown in DMEM supplemented with 10% FCS in a humidified 10% CO2 atmosphere, except as otherwise indicated.
Reverse Transcription (RT) PCR Detection of FasR and FasL mRNA Expression. RNA was isolated from cells by lysis in guanidine thiocyanate (Sigma Chemical Co., St. Louis, MO) followed by phenol extraction and ethanol precipitation, cDNA was synthesized using AMV reverse transcriptase (Promega Corp., Madison, WI) and random hexanucleotide primers (Boehringer Mannheim GmbH, Mannheim, Germany).
PCtL was performed on the cDNA using the following sense and antisense primers, respectively: FasR.: CAGAACTTGGA-AGGCCTGCATC and TCTGTTCTGCTGTGTCTTGGAC; FasL: GGATTGGGCCTGGGGATGTTTCA and TTGTGGCT-CAGGGGCAGGTTGTTG; {3-actin: GTGGGGCGCCCCAG-GCACCA and CTCCTTAATGTCACGCACGATTTC.
PCR. primers were designed using the DNASTAR Lasergene Primerselect program (DNASTAR, Inc., Madison, WI). Primer pairs were chosen to span introns in their genomic sequences, thus ensuring mR.NA-specific amplification. Primers were selected that showed insignificant homology to any other genes in the EMBL DNA sequence database. The FaslL primers span exons 3-6 and thus enable amplification of the three splice variants of FastL mRNA identified in normal activated lymphocytes that code for soluble forms of FasR. (25) .
Thermal cycling was as follows: denaturation at 96~ for 15 s; annealing at 55~ for 30 s, and extension at 72~ for 3 min. 40 cycles were performed for the FasR. and FasL PCRs, 35 cycles for the [3-actin PCiL. Primers were used at a final concentration of 0.1 ~M each, dNTPs at 50 IxM, and MgC12 at 1.5 raM. 1 U of Taq DNA polymerase was used per 50-txl reaction. PCR products were analyzed by electrophoresis through 2% agarose gels and viewed under UV light after ethidium bromide staining. HaelII-digested ~X174 DNA size markers were used. PCtL product specificities were confirmed by restriction mapping.
Immunohistochemical Detection of Cell Surface FasL. SW620 cells were cultured on glass chamber slides (Nunc, Inc., Naperville, IL). After fixation in 4% paraformaldehyde for 1 h, slides were washed twice for 5 rain in a wash buffer containing 50 mM Tris-C1, pH 7.6, 50 mM NaC1; and 0.001% saponin. Endogenous peroxidase was quenched with 3% hydrogen peroxide in methanol for 5 min. Slides were washed as before except that the wash buffer for this and all subsequent steps included 1% normal goat serum. Slides were then blocked for 1 h in wash buffer containing 5% normal goat serum. Slides were washed and incubated overnight at 4~ with a rabbit polyclonal anti-human FasL-specific IgG (Santa Cruz Biotechnology, Santa Cruz, CA) at 0.1 ~g ml-1 in wash buffer. Antibody binding was localized using a biotinylated secondary antibody, avidin-conjugated horseradish peroxidase, and diaminobenzidine substrate, contained within the Vectastain ABC detection kit (Vector Laboratories, Inc., Burlingame, CA). Staining with isotype-matched rabbit IgG was performed as a negative control. The immunizing peptide (NH2-terminal amino acids 2-19; Santa Cruz Biotechnology) was included at 1 ~g/ml -~ during the primary antibody incubation as a specific inhibitor of FasL staining in additional control staining. Slides were counterstained with hematoxylin.
Immunofluorescence How Cytometric Measurement of Cell Surface FasR. Mouse anti-human FasR. mAb (IgG0 was obtained from PharMingen (San Diego, CA). Adherent cells were harvested by scraping. Cells were washed in PBS and incubated with 5 Izg/ml -I mAb for 30 n-fin at 4~ and washed in PBS containing 2% FCS. FITC-conjugated secondary antibody (Dako Corp., Carpinteria, CA) was added to the cells for 30 min at 4~ Cells were washed again in PBS containing 2% FCS. Flow cytometric analysis was performed using a flow cytometer (Epics Elite; Coulter Corp., Hialeah, FL). 10,000 cells were examined for each determination. Isotype-matched control antibody was used in negative control staining.
Assessment of Anti-FasR mAb CHI 1-inducecl Apoptosis. Sensitivity of cells to Fas-mediated apoptosis was determined by treatment with the agonistic anti-Fastk CH11 IgM mAb (Kamiya Biomedical Co., Thousand Oaks, CA) or isotype control lgM at 0.1 b~g/ml -~. After antibody treatment, DNA was isolated from cells by the following procedure: cells were lysed in 0.5 ml of a buffer consisting of 100 mM Tris-C1, pH 8; 150 mM NaC1; 20 mM EDTA, and 0.8% sodium lauryl sarcosinate. P, NA was eliminated by the addition of 10 btl of 1LNase A (Boehringer Mannheim GmbH; at a concentration of 10 mg/ml in a buffer containing 10 mM Tris-C1, pH 7.6, and 15 mM NaC1 that was rendered DNase free by boiling for 15 rain followed by slow cooling to room temperature) and digesting for 1 h at 37~ Proteins were degraded by digestion with 10 ~1 of proteinase K (Boehringer Mannheim GmbH; 20 mg/ml in water) at 50~ for 2 h. Chromosomal DNA was then purified by a single phenol extraction followed by ethanol precipitation, after which the DNA pellet was redissolved in 20 btl of TE (10 mM Tris-C1, pH 8.0, and 1 mM EDTA). DNA integrity was assessed by electrophoresis through 2% agarose gels, DNA internucleosomal fragmentation or laddering being indicative of apoptosis.
Antisense Oligonucleotide Treatment. During antisense treatment, cells were maintained in reduced-serum medium (OptiMEM; Sigma Chemical Co.) to limit the degradation of oligonucleotides by serum-derived nucleases (26) . Oligonucleotide uptake was facilitated by complexing with the cationic lipid transfection reagent N- [1] [2] propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP), which has been shown to enhance DNA uptake by cells (27) . Complexing with DOTAP has also been shown to protect oligonucleotides from nucleolytic degradation within the cell. Cells were treated with oligonucleotides and the cationic lipid vector DOTAP (Boehringer Mannheim GmbH) at final concentrations of 10 and 13 ~M, respectively for 24 h. Oligonucleotides and the transfection reagent DOTAP were complexed at 100• concentration for 5 rain at Coculture DNA Fragmentation Assay (The JAM Test). Target Jurkat cell death resulting from coculture with effector colon cancer cells was quantitated by measurement of target cell DNA fragmentation using the JAM test (28) . The adherent colon cancer cells were seeded into the wells of a flat-bottomed 96-well microtiter plate at cell numbers appropriate to give the required E/T ratios. The cells thus seeded were incubated at 37~ for 24 h and aspirated before the addition of 2 • 104jurkat target cells. Target cell DNA was labeled by prior incubation with 10 p, Ci/ml of [3H]TdR at 37~ for 3 h. Oligonucleotide-treated cells were washed in culture medium (OptiMEM) before labeling. Labeled target cells were washed and added to the seeded effector cells in a final volume of 200 Ixl per well. After coculture at 37~ for 8 h, the cells were removed from the wells by pipetting up and down five times and were collected by filtration onto glass fiber filters using a 96-well filtration unit. The cells were hypotonically lysed, and fragmented DNA was washed through the filter by four washes of 0.25 ml of water. The radioactivity of intact chromosomal DNA retained on each filter was measured by liquid scintillation counting. Specific cell killing was calculated using the following equation: % Specific killing = (S -E/S) • 100 where E (experimental) is cpm of retained DNA in the presence of effector cells, and S (spontaneous) is cpm of retained DNA in the absence of effector cells. Use of the value of S rather than total incorporated counts in the equation corrects for spontaneous target cell DNA fragmentation during the assay.
Results and Discussion

FasR-bearing Colon Cancer Cells Are Resistant to Fas-mediated Induction of Apoptosis. R T -P C R results show that both
colon adenocarcinoma cell lines H T 2 9 and SW620, but neither esophageal squamous carcinoma ceU lines OC1 or OC2, express FasR m R N A (Fig 1) . The FasR R T -P C R assay was controlled by equalization of input R N A for each cell line. Comparable amplification efficiencies were achieved in all R N A samples as evidenced by the uniformity of control [3-actin R T -P C R product yields. Equivalent FasP( P C R product band intensities suggest that both HT29 and SW620 express levels of FasR qualitatively similar to that expressed in PHA-activated PBL. This was confirmed by detection of cell surface FasR on HT29 and SW620 cells by immunofluorescence flow cytometry after staining with a FasR-specific mAb (Fig. 2) . FasR staining was absent from OC1 and OC2.
FasR expression alone does not imply sensitivity to Fasmediated apoptosis, and other factors determine whether the FasL signal is transduced. Low FasR-expressing malignant glioma cells showed that a critical level of FasR expression is required for apoptotic signaling. Simply elevating subcritical FasR expression rendered these cells Fas sensitive (29) . Mutations of p53 have been associated with lack of FasR expression in transformed cells (30) . IFN-~/ and TNF-~x are required to potentiate FasR in some normal (31-33) and malignant (29, 34) cells. The Fas-sensitizing effect of these cytokines is partly associated with induction or upregulation of FasR expression. Indeed, IFN-3' has been shown to elevate FasR expression in HT29 (35) . As our results indicate, H T 2 9 and SW620 constitutively express levels of FasR m R N A comparable with that expressed in activated lymphocytes and cell surface FasR comparable with that expressed in Fas-sensitive Jurkat cells (see Fig. 5) . Hence, receptor level should be adequate for Fas signaling in these cells.
Log Fluorescence Intensity
FasP, function in HT29 and SW620 was assessed by treatment of these cells with the anti-FasR agonistic mAb CH11 and analysis of anti-FaslL-induced internucleosomal D N A cleavage. After 6-and 24-h incubations with this mAb, neither HT29 nor SW620 showed any evidence of apoptosis using the DNA fragmentation assay (Fig. 3) . After CH11 treatment, both cell types showed intact chromosomal DNA, equivalent in integrity to untreated cells incubated for 24 h. Both cell lines were as refractory to the effect of the anti-FasR agonistic mAb as the FasR-negative OC2 cell line. Under identical conditions, treatment of the Fas-sensitive Jurkat control cells with CH11 resulted in pronounced apoptotic DNA fragmentation into DNA ladders of nucleosomal oligomers of ~'-,180 bp after 6 h of treatment relative to the intact D N A of untreated Jurkat cells incubated for 24 h. Hence, HT29 and SW620, although expressing cell surface FasR, are resistant to induction of apoptosis through agonistic engagement of FaslL.
Expression of soluble, potentially antagonistic forms of FasP-, from splice variants of FasR m R N A lacking the transmembrane exon has been shown in some cells (36) and may contribute to Fas resistance in certain pathological conditions, including SLE (37, 38) . Three splice variants of FasP, mlLNA have been detected in normal activated lymphocytes (25) . Although a minor band was observed in the P,T-PCIL products from the HL60 control mlLNA, which corresponds to the Faslk Delta 1 m R N A splice variant, no PCP, product bands derived from amplification of spliced variants Delta 1, 2, or 3 (619-, 435-, or 372-bp expected product sizes, respectively) were detectable in any of the other cell lines. Hence, expression of soluble FasP, can be eliminated as a mechanism of Fas resistance in HT29 and SW620.
The level of expression of genes involved in the control of apoptosis can affect the Fas sensitivity of cells. Expression and upregulation of bcl 2 has been implicated in a variety of cell types as protective against apoptotic cell death, includ-
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The Fas Counterattack ing Fas-mediated apoptosis (34, (39) (40) (41) . Using immunofluorescence flow cytometry, we found that although SW620 expresses bcl 2, the level of expression in HT29 was negligible (unpublished observations), so that Fas resistance in these colon adenocarcinoma cells does not corelate with bcl 2 expression. Colon Cancer Cell SW620 Expresses FasL. R T -P C R results show that SW620, but none of the other cell lines HT29, OC1, or OC2, expresses FasL m R N A (Fig. 1) . The FasL P C R was performed on the same cDNA preparations used for the FasP,. and [3-actin control ILT-PCP, assays and was therefore similarly controled for equalization of input R N A and amplification efficiency. By comparing FasL R.T-PCR band intensities, SW620 expresses a level of FasL mP, NA qualitatively much higher than that expressed by PHA-activated PBL. Immunohistochemical staining shows that SW620 expresses cell surface FasL (Fig. 4) . FasL specificity was confirmed as staining of SW620 was inhibited by inclusion of the immunizing FasL peptide as a competitive inhibitor in the primary antibody incubation. These findings show that FasL expression is not restricted to lymphoid cells and tissues and sites of immune privilege in the body.
Using Fas-sensitive Jurkat indicator cells, FasL activity was undetectable in culture fluid conditioned by SW620 cells. Jurkat cells were incubated for 24 h in SW620 cellconditioned medium or mixtures of cell-conditioned and fresh media. This treatment failed to cause induction of apoptosis above background levels (10-15% in Jurkat cells) detectable by either the DNA fragmentation assay or flow cytometric detection of apoptotic bodies after propidium iodide staining of treated cells (unpublished observations). This suggests that the FasL expressed by SW620 is not shed by these cells.
Fas-sensitiue durkat T Cells Are Killed by Coculture with SW620.
Having demonstrated that SW620 cells express FasL, but are themselves resistant to Fas-mediated apoptosis, we wished to ascertain if the FasL was functional and therefore if SW620 could induce apoptosis in Fas-sensitive cells. In particular, we wished to know if SW620 cancer cells could kill activated, Fas-sensitive T cells in this way, which would suggest a potential mechanism of tumor immune escape. To address this question, we used Jurkat as a target cell in coculture experiments with SW620. Jurkat is a Fas-sensitive cell line o f T cell origin that is constitutively activated and has been widely used experimentally as a model for activated T cells, with which it shares functional similarities. Jurkat cells are particularly appropriate target cells for investigating putative FasL activity because they are insensitive to TNF-o~, another major mediator ofapoptotic cell death, and to lymphotoxin a (8) .
Using the DNA gel fragmentation assay, we observed that DNA from cocultured Jurkat and SW620 cells showed pronounced nucleosomal DNA laddering relative to either cell line incubated alone or to Jurkat cells cocultured with FasL-negative HT29 colon cancer cells. These preliminary results were suggestive of apoptotic killing of the Jurkat cells by the Fas-resistant, FasL-expressing SW620 cells. A more sensitive and controled coculture cell killing assay, Fig. 6 A, SW620 effected 30% specific killing of Jurkat cells at an E / T ratio o f 25:1 in an 8-h incubation. Cell killing increased with increasing E / T ratio, and pronounced killing (>20%) occurred even at a low E / T ratio equivalent to 5"1. face FasR staining to background levels. In the control nonsense oligonucleotide-treated cells, staining for FasR, was equivalent to that of untreated Jurkat cells (Fig. 5) . This indicates that antisense oligonucleotide treatment effectively and specifically abolishes FasR expression inJurkat cells.
In the J A M cell-kilhng test, it was found that FasR antisense oligonucleotide treatment completely protected Jurkat cells from killing by SW620 at all the tested E / T ratios (Fig. 6 A) . Control nonspecific oligonucleotide treatment had no effect on killing of Jurkat cells by SW620. As FasR antisense-treated Jurkat ceils were demonstrated to be FasP,. negative as opposed to the FasP,-positive n o n s e n s eoligonucleotide treated cells (Fig. 5) , these results strongly suggest that SW620 kills Jurkat ceils in a Fas-dependent manner.
FasL-specific Antisense Treatment Inhibits SW620 Killing of Jurkat T Cells. T o confirm that S W 6 2 0 -i n d u c e d killing of
Jurkat T cells was mediated by FasL, the SW620 cells were tested for cytotoxic activity after pretreatment with antisense oligonucleotides specific for the FasL gene. T h e J A M test was performed as described at an E / T ratio of 10:1, previously s h o w n to result in significant cell killing (Fig.  6 A) , with FasL-specific antisense and control nonsense oligonucleotide-treated SW620 effector cells. Although our results indicated that SW620 did not shed FasL at detectable levels, the SW620 cells were washed rigorously to eliminate the possibility of residual soluble SW620 on Jurkat T cells relative to the nonsense oligonucleotide-treated control SW620 cells (Fig. 6 B) . These data suggest that killing o f Jurkat cells was mediated by FasL expressed by SW620 cells.
The Fas
Counterattack. W e demonstrate that colon cancer cell SW620 expresses functional FasL and kills the activated T cell, Jurkat, in a Fas-dependent manner. W e also show that colon cancer cells SW620 and H T 2 9 express Figure 7 . Proposed Fas counterattack model of tumor immune escape in colon cancer. The colon cancer celt expresses FasP,. but is resistant to Fas-mediated T cell cytotoxicity. However, the colon cancer cell expresses functional FasL, which rapidly induces apoptosis in Fas-sensitive activated T cells, which infiltrate the tumor.
FasR but are resistant to Fas-mediated apoptosis. Although the cause(s) of Fas resistance in these cells remains to be elucidated, our results eliminate underexpression of cell surface FasK or expression of soluble Fastk as reasons for resistance.
Our results suggest a Fas counterattack model as a mechanism of immune escape in colon tumors (Fig. 7) . It shows how a tumor may exploit an intrinsic cell death program of the activated T cells that infiltrate it. Essentially the cancer cell counterattacks the activated cytotoxic T cell that challenges it with one of the T cell's own principal cytotoxic armaments: FasL. The counterattack is rendered more effective as the cancer cell itself is resistant to the cytotoxic effect of FasL, whereas the attacking T cell is inherently sensitive to its apoptotic death signal.
This mechanism is analogous to the recently established role of FasL in mediating immune privilege in mice. FasL expressed in tissues and at sites of immune privilege, such as the testis (14) and the anterior chamber of the eye (15) , induces apoptosis in activated lymphocytes that infiltrate these sites. Expression of functional FasL by human tumors could conceivably confer immune-privileged status on such malignancies.
Other selective advantages could theoretically accrue from expression by a tumor of such an important biological death factor to which the tumor cells themselves are resistant. FasL expression could conceivably facilitate the establishment of tumors or tumor metastases at sites where the indigenous cells express FasR and can therefore be rendered subject to the FasL-mediated cytotoxicity of the tumor. In this respect it is of interest that the FasL-expressing SW620 cell line was derived from a lymph node metastasis of a primary colon carcinoma.
Subsequent to the investigation of FasL expression and function in SW620, using KT-PCK, two other colon adenocarcinoma cell lines, T84 and CaCo2, were found to express FasL mRNA. This suggests that FasL expression may be a prevalent feature of colon carcinoma.
